TR201819211T4 - Kanserli Hastaların Taranmasına Yönelik Yöntemler Ve Kitler - Google Patents

Kanserli Hastaların Taranmasına Yönelik Yöntemler Ve Kitler Download PDF

Info

Publication number
TR201819211T4
TR201819211T4 TR2018/19211T TR201819211T TR201819211T4 TR 201819211 T4 TR201819211 T4 TR 201819211T4 TR 2018/19211 T TR2018/19211 T TR 2018/19211T TR 201819211 T TR201819211 T TR 201819211T TR 201819211 T4 TR201819211 T4 TR 201819211T4
Authority
TR
Turkey
Prior art keywords
cancer
patients
gene
patient
genes
Prior art date
Application number
TR2018/19211T
Other languages
English (en)
Turkish (tr)
Inventor
Galon Jérome
Pages Franck
Mlecnik Bernhard
Bindea Gabriela
Original Assignee
Hopitaux Paris Assist Publique
Inst Nat Sante Rech Med
Univ Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopitaux Paris Assist Publique, Inst Nat Sante Rech Med, Univ Paris Descartes filed Critical Hopitaux Paris Assist Publique
Publication of TR201819211T4 publication Critical patent/TR201819211T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
TR2018/19211T 2012-08-06 2013-08-05 Kanserli Hastaların Taranmasına Yönelik Yöntemler Ve Kitler TR201819211T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305975 2012-08-06

Publications (1)

Publication Number Publication Date
TR201819211T4 true TR201819211T4 (tr) 2019-01-21

Family

ID=46762994

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/19211T TR201819211T4 (tr) 2012-08-06 2013-08-05 Kanserli Hastaların Taranmasına Yönelik Yöntemler Ve Kitler

Country Status (13)

Country Link
US (2) US20150218650A1 (https=)
EP (2) EP3470531A1 (https=)
JP (2) JP6559566B2 (https=)
AU (1) AU2013301609B2 (https=)
CA (1) CA2881389C (https=)
DK (1) DK2880180T3 (https=)
ES (1) ES2702722T3 (https=)
LT (1) LT2880180T (https=)
PL (1) PL2880180T3 (https=)
PT (1) PT2880180T (https=)
SG (1) SG11201500922RA (https=)
TR (1) TR201819211T4 (https=)
WO (1) WO2014023706A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
RU2020127099A (ru) * 2014-08-19 2020-09-02 Нэшнл Юниверсити Корпорейшн Окаяма Юниверсити Способ улучшения функции иммунных клеток и оценки мультифункциональности иммунных клеток
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
US20190309369A1 (en) * 2016-05-09 2019-10-10 Inserm (Institute National De La Sante Et De La Recherche Medicale) Methods for classifying patients with a solid cancer
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
US11311945B2 (en) 2018-03-22 2022-04-26 Sumitomo Electric Hardmetal Corp. Surface-coated cutting tool and method for manufacturing same
US20210381058A1 (en) * 2018-10-01 2021-12-09 Nantomics, Llc Evidence based selection of patients for clinical trials using histopathology
CN114072676B (zh) 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
CA3151629A1 (en) 2019-11-07 2021-05-14 Laura E. BENJAMIN Classification of tumor microenvironments
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
CN115997123A (zh) 2020-06-30 2023-04-21 国家医疗保健研究所 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
JP7741831B2 (ja) 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
EP2157524A3 (en) * 2003-09-03 2010-12-08 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods for identifying, diagnosing, and predicting survival of lymphomas
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
US20060246523A1 (en) 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
DK2963011T3 (en) 2005-11-23 2018-08-06 Ventana Med Syst Inc MOLECULAR CONJUGATE
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
PT2619576T (pt) * 2010-09-24 2020-09-14 Niels Grabe Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro
DK3141617T3 (en) * 2011-01-11 2019-02-25 Inst Nat Sante Rech Med PROCEDURE FOR PREVENTING THE CANCER OF A CANCER ON A PATIENT BY ANALYZING GENEPRESSION

Also Published As

Publication number Publication date
JP2015530877A (ja) 2015-10-29
JP6559566B2 (ja) 2019-08-14
JP6995091B2 (ja) 2022-01-14
PT2880180T (pt) 2018-12-27
EP2880180B1 (en) 2018-10-03
EP2880180A1 (en) 2015-06-10
AU2013301609A1 (en) 2015-02-26
CA2881389A1 (en) 2014-02-13
EP3470531A1 (en) 2019-04-17
WO2014023706A1 (en) 2014-02-13
US20200299784A1 (en) 2020-09-24
LT2880180T (lt) 2019-01-25
US20150218650A1 (en) 2015-08-06
JP2019176880A (ja) 2019-10-17
AU2013301609B2 (en) 2019-03-14
CA2881389C (en) 2022-01-04
PL2880180T3 (pl) 2019-04-30
DK2880180T3 (en) 2019-01-14
ES2702722T3 (es) 2019-03-05
SG11201500922RA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
JP6995091B2 (ja) 癌患者をスクリーニングするための方法及びキット
US12291752B2 (en) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
AU2017261685B2 (en) Methods for classifying patients with a solid cancer
Mahadevan et al. Gene expression and serum cytokine profiling of low stage CLL identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as regulators of cell proliferation, survival and migration
US20260049359A1 (en) Prediction of response to immune therapy in breast cancer patients
US20250320564A1 (en) Methods and kits for treatment of cancer patients who are good responders to antitumoral treatment
WO2018011166A2 (en) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055327A1 (en) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055322A1 (en) Methods for quantifying the population of neutrophils in a tissue sample
KR102431271B1 (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도
JP2020509354A (ja) がんの重症度を評価するためのｔｉｍ−３
WO2017055320A1 (en) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055321A1 (en) Methods for quantifying the population of fibroblasts in a tissue sample
HK40007449A (en) Methods for classifying patients with a solid cancer
HK40007449B (en) Methods for classifying patients with a solid cancer
BR112018072993B1 (pt) Método in vitro para o prognóstico do tempo de sobrevivência de um paciente que sofre de um câncer sólido e método in vitro para avaliar a capacidade de resposta de um paciente que sofre de um câncer sólido a um tratamento antitumoral
WO2017055326A1 (en) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055325A1 (en) Methods for quantifying the population of nk cells in a tissue sample